Promising trial for Alzheimer's treatment

Eli Lilly last week announced the results of a Phase 3 trial on its experimental drug called Donanemab. The latest drug trial in a new class of Alzheimer’s drugs gives researchers and advocates renewed hope of slowing the progression of the brain disease.